1 이택진, "활동성 폐결핵 환자의 소아청소년 접촉자 조사 결과: 2012년부터 2014년까지 단일 기관의 경험" 대한소아감염학회 22 (22): 91-96, 2015
2 민동훈, "폐결핵 환자와 접촉한 소아의 잠복결핵 진단에 영향을미치는 위험 요소" 대한 소아알레르기 호흡기학회 5 (5): 105-110, 2017
3 이민현, "새로 진단된 결핵 환자의 가족 내 2차 감염 양상 조사" 대한소아감염학회 22 (22): 7-15, 2015
4 Schechter M, "Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts" 173 : 922-926, 2006
5 Joint Committee for the Revision of Korean Guidelines for Tuberculosis, "Tuberculosis in children and adolescents. In: Korean guidelines for tuberculosis" Korea Centers for Disease Control and Prevention
6 Frydenberg AR, "Toxicity of first-line drugs for treatment of tuberculosis in children: review" 14 : 1329-1337, 2009
7 Marais BJ, "The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era" 8 : 392-402, 2004
8 Spyridis NP, "The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study" 45 : 715-722, 2007
9 Marais BJ, "The clinical epidemiology of childhood pulmonary tuberculosis: a critical review of literature from the pre-chemotherapy era" 8 : 278-285, 2004
10 World Health Organization, "TABLE A4.1. TB incidence estimates, 2017 & TABLE A4.2. Estimates of TB mortality, 2017. In: Global tuberculosis report 2018" World Health Organization
1 이택진, "활동성 폐결핵 환자의 소아청소년 접촉자 조사 결과: 2012년부터 2014년까지 단일 기관의 경험" 대한소아감염학회 22 (22): 91-96, 2015
2 민동훈, "폐결핵 환자와 접촉한 소아의 잠복결핵 진단에 영향을미치는 위험 요소" 대한 소아알레르기 호흡기학회 5 (5): 105-110, 2017
3 이민현, "새로 진단된 결핵 환자의 가족 내 2차 감염 양상 조사" 대한소아감염학회 22 (22): 7-15, 2015
4 Schechter M, "Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts" 173 : 922-926, 2006
5 Joint Committee for the Revision of Korean Guidelines for Tuberculosis, "Tuberculosis in children and adolescents. In: Korean guidelines for tuberculosis" Korea Centers for Disease Control and Prevention
6 Frydenberg AR, "Toxicity of first-line drugs for treatment of tuberculosis in children: review" 14 : 1329-1337, 2009
7 Marais BJ, "The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era" 8 : 392-402, 2004
8 Spyridis NP, "The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study" 45 : 715-722, 2007
9 Marais BJ, "The clinical epidemiology of childhood pulmonary tuberculosis: a critical review of literature from the pre-chemotherapy era" 8 : 278-285, 2004
10 World Health Organization, "TABLE A4.1. TB incidence estimates, 2017 & TABLE A4.2. Estimates of TB mortality, 2017. In: Global tuberculosis report 2018" World Health Organization
11 Ena J, "Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis" 40 : 670-676, 2005
12 Joint Committee for the Revision of Korean Guidelines for Tuberculosis, "National Tuberculosis Control Program. In: Korean guidelines for tuberculosis" Korea Centers for Disease Control and Prevention
13 Joint Committee for the Revision of Korean Guidelines for Tuberculosis, "Korean guidelines for tuberculosis" Korea Centers for Disease Control and Prevention
14 World Health Organization, "BOX 1.1. Basic facts about TB & Chapter 1. Introduction. In: Global tuberculosis report 2018" World Health Organization
15 Kim JH, "Achievements in and challenges of tuberculosis control in South Korea" 21 : 1913-1920, 2015
16 Korea Centers for Disease Control and Prevention, "2018 National tuberculosis program guideline" Korea Centers for Disease Control and Prevention